Vision Session: U.S. Office of Inspector General - From Analytics to Action: A Law Enforcement Perspective on the Use of Data Analytics to Combat Rx Drug Diversion
We honor ourselves when we speak out for recovery. We show the world that recovery matters because it brings hope and peace into the lives of individuals and their loved ones. ~ Beth Wilson
The only person you are destined to become is the person you decide to be. ~ Ralph Waldo Emerson
Success is the sum of small efforts, repeated day in and day out.
~ Robert Collier
Vision Session: U.S. Office of Inspector General - From Analytics to Action: A Law Enforcement Perspective on the Use of Data Analytics to Combat Rx Drug Diversion
We honor ourselves when we speak out for recovery. We show the world that recovery matters because it brings hope and peace into the lives of individuals and their loved ones. ~ Beth Wilson
The only person you are destined to become is the person you decide to be. ~ Ralph Waldo Emerson
Success is the sum of small efforts, repeated day in and day out.
~ Robert Collier
TRAINING 2 Unpacking Tennessee Adolescent Substance Misuse DataKarenChenoaSergent
An overview of state (Tennessee) and county-level adolescent substance use data to include a summary of TN Together adolescent survey results from 2018/2019.
Biomedical Informatics project for implementing a state wide screening program for narcotic seeking patients. Project defined from abstract to specific implementation and measurement criteria.
When: June 10, 2021
Only 5% of rare diseases have an approved drug therapy. Only 60% of orphan medicines approved by the US FDA or EU EMA are approved in Canada, and often many months or years later. Only 34% of approved orphan medicines are funded by Canadian public drug plans. Under the BEST of circumstances, only 10% of eligible patients get access to an approved medicine. And worldwide, only 1% of rare disease patients will receive an approved drug. Most without treatment are children. How can Canada’s Rare Disease Drug Strategy assure all eligible Canadian patients get access to the most appropriate medicine for their individual needs?
Two panels will be tasked to consider a “Canada Leading the Way” strategic pharmaceutic framework that (1) attracts early investment in R&D; (2) reduces and manages risk for early adoption of innovative therapies; and (3) leads to a sustained culture of collaboration and trust among all stakeholders, including regulators, industry, payers, and patients. In particular, what has Canada learned from addressing COVID, for example, in terms of screening, diagnosis, drug repurposing, vaccine procurement, timely intervention, and monitoring, that can apply directly to rare disease therapies?
Politico Pro Health Care Briefing: Drug Safety and the Trump FDACVS Health
Opening remarks by Thomas M. Moriarty, Executive Vice President, Chief Strategy Officer and General Counsel at the Politico Pro Health Care Briefing: Drug Safety and the Trump FDA, April 5, 2017.
For more on CVS Health's work to ensure access to affordable drugs, visit: http://cvshealth.com/thought-leadership/drug-costs-efficiency-and-the-future-of-the-fda
July 22, 2021 : Aligning on Rare Drug Strategy, PMPRB, and Federal Election
Engage with our Expert Panel in a Townhall style meeting to add your voice on these important issues in preparation for upcoming federal election.
Panelist
Alexandra Chambers (Novartis)
Peter Brenders (BeiGene)
Angela Genge (The Neuro)
Fred Horne (3Sixty Public Affairs)
Leanne Ward (CHEO)
Addressing Rising Health Care Costs | CVS HealthCVS Health
CVS Health is committed to lowering health care costs while delivering high-quality care to communities across the country. Learn more: https://cvshealth.com/thought-leadership/addressing-rising-health-care-costs
TRAINING 2 Unpacking Tennessee Adolescent Substance Misuse DataKarenChenoaSergent
An overview of state (Tennessee) and county-level adolescent substance use data to include a summary of TN Together adolescent survey results from 2018/2019.
Biomedical Informatics project for implementing a state wide screening program for narcotic seeking patients. Project defined from abstract to specific implementation and measurement criteria.
When: June 10, 2021
Only 5% of rare diseases have an approved drug therapy. Only 60% of orphan medicines approved by the US FDA or EU EMA are approved in Canada, and often many months or years later. Only 34% of approved orphan medicines are funded by Canadian public drug plans. Under the BEST of circumstances, only 10% of eligible patients get access to an approved medicine. And worldwide, only 1% of rare disease patients will receive an approved drug. Most without treatment are children. How can Canada’s Rare Disease Drug Strategy assure all eligible Canadian patients get access to the most appropriate medicine for their individual needs?
Two panels will be tasked to consider a “Canada Leading the Way” strategic pharmaceutic framework that (1) attracts early investment in R&D; (2) reduces and manages risk for early adoption of innovative therapies; and (3) leads to a sustained culture of collaboration and trust among all stakeholders, including regulators, industry, payers, and patients. In particular, what has Canada learned from addressing COVID, for example, in terms of screening, diagnosis, drug repurposing, vaccine procurement, timely intervention, and monitoring, that can apply directly to rare disease therapies?
Politico Pro Health Care Briefing: Drug Safety and the Trump FDACVS Health
Opening remarks by Thomas M. Moriarty, Executive Vice President, Chief Strategy Officer and General Counsel at the Politico Pro Health Care Briefing: Drug Safety and the Trump FDA, April 5, 2017.
For more on CVS Health's work to ensure access to affordable drugs, visit: http://cvshealth.com/thought-leadership/drug-costs-efficiency-and-the-future-of-the-fda
July 22, 2021 : Aligning on Rare Drug Strategy, PMPRB, and Federal Election
Engage with our Expert Panel in a Townhall style meeting to add your voice on these important issues in preparation for upcoming federal election.
Panelist
Alexandra Chambers (Novartis)
Peter Brenders (BeiGene)
Angela Genge (The Neuro)
Fred Horne (3Sixty Public Affairs)
Leanne Ward (CHEO)
Addressing Rising Health Care Costs | CVS HealthCVS Health
CVS Health is committed to lowering health care costs while delivering high-quality care to communities across the country. Learn more: https://cvshealth.com/thought-leadership/addressing-rising-health-care-costs
Intro to Prevention: Psychopharmacology Guest LectureJulie Hynes
Current A&D Conditions in lane County: And why we need prevention. Guest lecturer: Julie Hynes, MA, RD, CPS - PreventionLane at Lane County Public Health
Global Medical Cures™ | Responding to America's Prescription Drug Abuse CrisisGlobal Medical Cures™
Global Medical Cures™ | Responding to America's Prescription Drug Abuse Crisis
DISCLAIMER-
Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
The PRC Region 8 Regional Needs Assessment (RNA) is a report of the 28 counties of South Central Texas assessing the substance abuse trends and gaps in resources. This is the more condensed version of the RNA indemnifying the major points that came out of the full RNA.
The abuse of illegal substances has been a major problem faced by the Maldives for the past 3 decades now. The country recognised this as a problem for the first time in the late 1970s. Over the years, with the increase in the number of substance abusers, addictive subculture developed gradually.
Dr. Tom Frieden, Director of the Centers for Disease Control and Prevention, keynote presentation at the National Rx Drug Abuse & Heroin Summit on March 30, 2016.
Kana Enomoto, Acting Administrator, Substance Abuse and Mental Health Services Administration, keynote presentation at the National Rx Drug Abuse & Heroin Summit March 29, 2016
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
3. Source of Prescription Pain Relievers
Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2009-2010
4. • Coordinated effort across
the Federal Government
• Four focus areas:
1) Education
2) Prescription Drug
Monitoring Programs
3) Proper Disposal of
Medication
4) Enforcement
Prescription Drug Abuse
Prevention Plan
5. Source: PDMP Training and Technical Assistance Center, Brandeis University, 2013
Prescription Drug Monitoring Programs
6. How to Recognize and Respond
to an Opioid Overdose
• The American Society of Anesthesiologists (ASA) has
created a card explaining how to recognize and respond
to an opioid overdose.
• The card, called “Opioid Overdose Resuscitation,” is
available for download on the ASA Web site.
• To download the card, go to: http://www.asahq.org/
WhenSecondsCount/resources
7. • There are signs that efforts to reduce and prevent prescription drug
abuse are working.
o National data show the rate of past-month nonmedical use of prescription
medicines among young adults aged 18 to 25 over the past two years is lower
than the rate from 2003 - 2010.1
• State public health and public safety professionals can take steps to
promote safer prescribing practices; improved prescription monitoring;
safe disposal; and effective monitoring, intervention, treatment and
overdose prevention.
• Long-term success will come from coordination and collaboration at the
Federal, state, local, and tribal levels, particularly among public health and
public safety leaders.
Conclusion
1 Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National
Findings. U.S. Department of Health and Human Services. [September 2013]. Available: http://www.samhsa.gov/data/NSDUH/
2012SummNatFindDetTables/NationalFindings/NSDUHresults2012.htm